Saturday 7 November 2026
Export JANX’s income statement to Excel — free account
Janux Therapeutics, Inc.
JANX Healthcare Biotechnology
Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- +12.8%
- Free cash flow
- −94.5%
Quarter to September 2026, against a year earlier
17.63
1.57
+9.78%
Follow JANX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
— | — | — | 4 |
| (11.48%) | (11.72%) | (10.70%) | (10.58%) | ||
| (11.02%) | (11.01%) | (10.06%) | (9.94%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(11.90%) | (12.09%) | (11.07%) | (11.00%) | |
Average Days of Receivables |
— | 901.43 | 2.27 | 4.51 | |
Free Cash Flow per Share |
(1.34) | (1.25) | (0.67) | (0.86) | |
Free Cash Flow |
(83.28) | (78.49) | (41.92) | (54.16) | |
Capital Expenditures |
(1.04) | (0.94) | (0.67) | (0.58) | |
| Other line items | |||||
Cash ROIC |
(4.33%) | (4.14%) | (2.21%) | (2.92%) | |
Accounts Receivable Turnover |
— | 0.78 | 25.96 | 71.59 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 900.75% | 516.60% | 360.24% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 303.85% | 181.55% | 128.96% | |
Share Based Compensation of Revenue |
0.00% | 273.69% | 153.71% | 109.29% | |
Operating CF/Net income |
0.72 | 0.68 | 0.40 | 0.54 | |
Depreciation/Fixed assets |
(4.04) | (3.95) | (3.61) | (3.76) | |
Capex/Depreciation |
0.07 | 0.07 | 0.06 | 0.06 | |
Revenue per Share |
0.00 | 0.23 | 0.38 | 0.53 | |
Operating CF per Share |
(1.33) | (1.24) | (0.66) | (0.85) | |
Capex per Share |
(0.02) | (0.02) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.07 | 0.03 | 0.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026